vimarsana.com
Home
Live Updates
Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors : vimarsana.com
Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors : vimarsana.com
Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors
/PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced...
Related Keywords
Italy ,
Louisiana ,
United States ,
New Orleans ,
Ankara ,
Turkey ,
Rome ,
Lazio ,
Switzerland ,
American ,
Eleanor Perkin ,
Rick Davis ,
Anna Morena Dalise ,
Sylvie Berrebi ,
American Association For Cancer Research ,
Linkedin ,
Clinical Research ,
Ernestn Morial Convention Center ,
Late Breaking ,
Cancer Research ,
Microsatellite Instable High ,
Presentation Details ,
Microsatellite Instability ,
Late Breaking Research ,
Convention Center ,
Anna Morenad Alise ,
Great Ape Adenoviral ,
Modified Vaccinia Ankara ,
Nouscom ,